Kyntra Bio, Inc. (KYNB) - Total Assets
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) holds total assets worth $119.59 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore KYNB cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Kyntra Bio, Inc. - Total Assets Trend (2012–2025)
This chart illustrates how Kyntra Bio, Inc.'s total assets have evolved over time, based on quarterly financial data. See net assets of Kyntra Bio, Inc. for net asset value and shareholders' equity analysis.
Kyntra Bio, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Kyntra Bio, Inc.'s total assets of $119.59 Million consist of 82.8% current assets and 17.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.0% |
| Accounts Receivable | $216.00K | 0.2% |
| Inventory | $3.74 Million | 3.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Kyntra Bio, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Kyntra Bio, Inc. stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kyntra Bio, Inc.'s current assets represent 82.8% of total assets in 2025, an increase from 19.9% in 2012.
- Cash Position: Cash and equivalents constituted 40.0% of total assets in 2025, up from 14.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 3.1% of total assets.
Kyntra Bio, Inc. Competitors by Total Assets
Key competitors of Kyntra Bio, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €249.51 Million |
|
CorMedix Inc
NASDAQ:CRMD
|
USA | $826.14 Million |
Kyntra Bio, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.39 | 1.47 | 3.72 |
| Quick Ratio | 3.26 | 1.45 | 3.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $69.83 Million | $63.20 Million | $454.65 Million |
Kyntra Bio, Inc. - Advanced Valuation Insights
This section examines the relationship between Kyntra Bio, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 80.40 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -44.3% |
| Total Assets | $119.59 Million |
| Market Capitalization | $27.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kyntra Bio, Inc.'s assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kyntra Bio, Inc.'s assets decreased by 44.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kyntra Bio, Inc. (2012–2025)
The table below shows the annual total assets of Kyntra Bio, Inc. from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $119.59 Million | -44.25% |
| 2024-12-31 | $214.53 Million | -49.35% |
| 2023-12-31 | $423.53 Million | -30.58% |
| 2022-12-31 | $610.09 Million | -21.16% |
| 2021-12-31 | $773.82 Million | -6.41% |
| 2020-12-31 | $826.84 Million | -3.56% |
| 2019-12-31 | $857.40 Million | -2.63% |
| 2018-12-31 | $880.60 Million | -2.01% |
| 2017-12-31 | $898.65 Million | +91.38% |
| 2016-12-31 | $469.55 Million | -0.22% |
| 2015-12-31 | $470.57 Million | -2.68% |
| 2014-12-31 | $483.53 Million | +62.83% |
| 2013-12-31 | $296.95 Million | +11.81% |
| 2012-12-31 | $265.59 Million | -- |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more